Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney, Sara M; Barry, William T; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew; Shapira, Iuliana; Wolff, Antonio C; Carey, Lisa A; Overmoyer, Beth A; Partridge, Ann H; Guo, Hao; Hudis, Clifford A; Krop, Ian E; Burstein, Harold J; Winer, Eric P

Tolaney, Sara M; Barry, William T; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew; Shapira, Iuliana; Wolff, Antonio C; Carey, Lisa A; Overmoyer, Beth A; Partridge, Ann H; Guo, Hao; Hudis, Clifford A; Krop, Ian E; Burstein, Harold J; Winer, Eric P.

Affiliation

Tolaney SM; From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medica

N Engl J Med ; 372(2): 134-41, 2015 Jan 08.

Article in En | MEDLINE | ID: mdl-25564897

Subject(s)

Adenocarcinoma/drug therapy; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Paclitaxel/administration & dosage; Adenocarcinoma/chemistry; Adenocarcinoma/mortality; Adenocarcinoma/therapy; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/chemistry; Breast Neoplasms/mortality; Breast Neoplasms/therapy; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel/adverse effects; Radiotherapy; Receptor, ErbB-2/analysis; Receptor, ErbB-2/immunology; Survival Rate; Trastuzumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Breast Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: N Engl J Med Year: 2015 Document type: Article

Fulltext

XML

PubMed Links

Search on Google